Study context
- Study design
- Preclinical animal study
- Population or model
- Animal model; verify the species in the source
Research question
What does this source report about NAD+, and what evidence model and limitations apply?
Limitations
Confirm the complete study design, intervention identity, population or model, outcomes, statistical context, and limitations in the linked source before approval.
Original source
Nicotinamide Adenine Dinucleotide-Loaded Lubricated Hydrogel Microspheres with a Three-Pronged Approach Alleviate Age-Related Osteoarthritis.
Yanpeng Lin, Hangtian Wu, Jun Wang, Wanling He, Jiahui Hou, Vidmi Taolam Martin, Chencheng Zhu, Yupeng Chen, Junyuan Zhong, Bin Yu, Aiping Lu, Daogang Guan, Genggeng Qin, Weiguo Chen · ACS nano · 2025
Source abstract
Chondrocyte senescence, synovitis, and decreased level of lubrication play pivotal roles in the pathogenesis of age-related osteoarthritis (AROA). However, there are currently no effective therapeutic interventions capable of altering the progression of OA until it reaches advanced stages, necessitating joint replacement. In this study, lubricious and drug-loaded hydrogel microspheres were designed and fabricated by utilizing microfluidic technology for radical polymerization of chondroitin sulfate methacrylate and incorporating nicotinamide adenine dinucleotide (NAD)-loaded liposomes modified with lactoferrin that are positively charged. Mechanical, tribological, and drug release analyses demonstrated enhanced lubrication properties and an extended drug dissemination time for the NAD@NPs@HM microspheres. In vitro assays unveiled the ability of NAD@NPs@HM to counteract chondrocyte senescence. RNA sequencing analysis, untargeted metabolomics analysis, and in vitro experiments on macrophages revealed that NAD@NPs@HM can regulate the metabolic reprogramming of synovial macrophages, promoting their repolarization from the M1 to M2 phenotype, thereby alleviating synovitis. Intra-articular injection of NAD@NPs@HM in aged mice reduced the mechanisms associated with AROA. These results suggest that NAD@NPs@HM may provide extended drug release, improved joint lubrication leading to better gait, and attenuation of AROA pathogenic processes, indicating its potential as a therapeutic approach for AROA.
Related product
Review the complete product page, COAs, specifications, and all approved research sources.
NAD+ research pageThis educational summary helps you review the cited source in context. The third-party article is not reproduced, and the citation does not imply endorsement of a related product.
